76,25 €
14,77 % gestern
L&S, 30. Oktober, 22:54 Uhr
ISIN
US3773221029
Symbol
GKOS
Berichte

Glaukos Corp Aktie News

Positiv
The Motley Fool
etwa 5 Stunden alt
The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.
Neutral
Seeking Alpha
ein Tag alt
Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Divisi...
Neutral
Business Wire
ein Tag alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% ...
Positiv
Reuters
11 Tage alt
The U.S. Food and Drug Administration has approved a new eye therapy from Glaukos Corp , giving patients a less painful and more convenient option to treat a progressive condition that can severely affect vision, the company said on Monday.
Neutral
Business Wire
11 Tage alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). Epioxa is a groundbreaking advanc...
Neutral
Business Wire
17 Tage alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held Oct...
Neutral
Business Wire
23 Tage alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The company's management will discuss the results during a...
Neutral
Business Wire
etwa ein Monat alt
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a ma...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen